The Food and Drug Administration on Thursday delayed the approval of a treatment for patients with congestive heart failure.
The agency is reviewing the data needed to support the drug, and the agency expects to take at least six months to complete the review, according to a statement from FDA spokeswoman Jennifer DeLong.
The FDA will consider a review request if there is no significant new evidence to support transfusion therapy, according the statement.
This is not a new issue for the agency, which has already taken a tougher stance on the drug.
Last year, the FDA blocked the drug from entering the market after researchers showed it could exacerbate the symptoms of patients with COPD.
But the agency is still looking for new data, which could mean it will approve the drug sooner than it otherwise would have.
Transfusion therapy is a common treatment for congestive cardiomyopathy, a common disease that can result in heart failure if left untreated.
Doctors typically inject the blood of a healthy person into a patient’s body, which causes the person’s heart to pump more blood into the body.
The drug is used to treat congestive hearts that fail to develop normally or have heart attacks.
Patients who have COPD have a higher risk of having their heart attack or stroke.
Researchers have shown that transfusion could be an effective treatment for this condition, but it’s not yet proven that it can prevent heart attacks or strokes, according.
In addition, there is also some evidence that transfusions can cause problems with the heart, including heart valve issues.